Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET
Company Participants
Tram Bui - Vice President, Investor Relations and Corporate Communications
Helen Torley - President and Chief Executive Officer
Nicole LaBrosse - Chief Financial Officer
Conference Call Participants
Mohit Bansal - Wells Fargo
Michael DiFiore - Evercore ISI
Corinne Jenkins - Goldman Sachs
Jason Butler - JMP Securities
Vikram Purohit - Morgan Stanley
Mitchell Kapoor - H.C Wainwright
Operator
Hello and welcome to the Halozyme Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
I will now turn the conference over to Tram Bui, Vice President of Investor Relations and Corporate Communications. Please go ahead.
Tram Bui
Thank you, operator. Good afternoon and welcome to our third quarter 2023 financial and operating results conference call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call, in the Investor Relations section of our website.
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer who will provide an update on our business. And Nicole LaBrosse, our Chief Financial Officer, who will review our financial results for the third quarter 2023.
On today's call we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation.
I'll now turn the call over to Dr. Helen Torley.
Helen Torley
Thank you, Tram. And good afternoon, everyone. We're very pleased with our third quarter and year-to-date 2023 financial and operating results, which reflect the continued strength and durability of our business. We remain focused on supporting our growth trajectory and are well positioned for another record year. We are on track to meet our recently updated revenue guidance and deliver greater than 25% revenue growth for the year, including greater than 23% royalty revenue growth.
I'm also pleased to announce that as a result of our operational performance and close attention to expenses we are raising EBITDA and non-GAAP EPS guidance. EBITDA guidance has increased from $420 million to $440 million to $430 million to $445 million. And non-GAAP EPS guidance from $2.65 to $2.75 to $2.70 to $2.80. I'm pleased to forecast a strong performance on both top and bottom line growth this year.